Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Credit agrmnt [a]
Appointed director
Inv. presentation
Quarterly results
Acq. announced
Director departure
Bausch Health Companies Inc. (BHC) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/02/2023 4 Paulson John (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 7,603 shares @ $8.22, valued at $62.5k
10/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/29/2023 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...
Docs: "Indenture, by and among Bausch + Lomb Corporation, the guarantors party thereto and Citibank, N.A., acting through its agency and trust division, as trustee, and as notes collateral agent thereto",
"Credit Agreement, as amended by the First Incremental Amendment, by and among Bausch + Lomb Corporation, certain subsidiaries of Bausch + Lomb Corporation as subsidiary guarantors, the lenders party thereto, Citibank, N.A., as collateral agent thereto, Goldman Sachs Bank USA, as term facility administrative agent thereto and JPMorgan Chase Bank, N.A., as first incremental term facility administrative agent thereto",
"Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA ® LAVAL, Quebec, September 29, 2023 - Bausch + Lomb Corporation , a subsidiary of Bausch Health Companies Inc. , today announced it has completed its acquisition of XIIDRA ® 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets. Under the terms of the agreement, Bausch + Lomb, through an affiliate, acquired XIIDRA ® and the other ophthalmology assets from Novartis for up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations of up to $750 million based on sales thresholds and pipeline commercialization. Bausch + Lomb also acqu..."
09/29/2023 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/03/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2023 RESULTS, OTHER KEY UPDATES FROM THE QUARTER, AND RAISES FULL-YEAR 2023 REVENUE OUTLOOK"
07/19/2023 SD Form SD - Specialized disclosure report:
07/07/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Stock and Asset Purchase Agreement by and among Buyer, Novartis and, for the limited purposes set forth therein, Bausch + Lomb",
"Stock and Asset Purchase Agreement by and among Buyer, Novartis and, for the limited purposes set forth therein, Bausch + Lomb"
07/07/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Credit and Security Agreement, by and among Bausch Receivables Funding LP, as Borrower, Bausch Receivables Funding GP ULC, Bausch Health US, LLC, as the Master Servicer, GLAS USA LLC, as Administrative Agent, GLAS Americas LLC, as Collateral Agent, KKR Capital Markets LLC, as Left Lead Arranger, KKR Credit Advisors (US) LLC, as Structuring Advisor, and the Lenders from time to time party thereto",
"Bausch Health Enters Into $600 Million Financing Facility With KKR LAVAL, Quebec, July 7, 2023 - Bausch Health Companies Inc. and KKR today announced that Bausch Receivables Funding LP, an Ontario limited partnership and wholly-owned subsidiary of Bausch Health, has entered into a $600 million non-recourse financing facility with KKR and its credit funds and accounts. The facility will be collateralized by certain accounts receivables originated by a wholly-owned subsidiary of Bausch Health. Bausch Health expects to utilize the proceeds from the facility for general corporate purposes. The facility provides access to additional liquidity for a term of approximately five years. Houlihan Lokey, Inc. acted as the Company's financial advisor. Finacity Corporation acted as the administrator for..."
07/05/2023 4 WECHSLER AMY B (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 859 shares @ $8, valued at $6.9k
07/05/2023 4 ICAHN BRETT (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 4,140 shares @ $8, valued at $33.1k
07/05/2023 4 Paulson John (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 7,812 shares @ $8, valued at $62.5k
07/05/2023 4 ROBERTSON RUSSEL C (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 3,906 shares @ $8, valued at $31.2k
06/30/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SECURITIES AND EXCHANGE COMMISSION",
"Bausch Health's Bausch + Lomb to Acquire Novartis' XIIDRA ® LAVAL, Quebec, June 30, 2023 - Bausch + Lomb Corporation , a subsidiary of Bausch Health Companies Inc. , announced that it has entered into a definitive agreement with Novartis to acquire XIIDRA ® 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye. Under the terms of the agreement, Bausch + Lomb, through an affiliate, has agreed to acquire XIIDRA, libvatrep and AcuStream from Novartis for up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations up to $750 million based on sales thresholds and pipeline commercialization. Bausch + Lomb will also bring on the sales force supporting X..."
05/19/2023 4 Paulson John (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 29,205 shares @ $0
05/19/2023 4 WECHSLER AMY B (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 29,205 shares @ $0
05/19/2023 4 Ross Thomas W. Sr. (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 29,205 shares @ $0
05/19/2023 4 ROBERTSON RUSSEL C (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 29,205 shares @ $0
05/19/2023 4 POWER ROBERT N (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 29,205 shares @ $0
05/19/2023 4 Mulligan Richard (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 29,205 shares @ $0
05/19/2023 4 Miller Steven D (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 29,205 shares @ $0
05/19/2023 4 KAVANAGH SARAH B (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 29,205 shares @ $0
05/19/2023 4 ICAHN BRETT (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 29,205 shares @ $0
05/17/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/06/2023 ARS Form ARS - Annual Report to Security Holders:
04/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/06/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/04/2023 4 WECHSLER AMY B (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 848 shares @ $8.1, valued at $6.9k
04/04/2023 4 ROBERTSON RUSSEL C (Director) has filed a Form 4 on Bausch Health Companies Inc.
Txns: Granted 4,110 shares @ $8.1, valued at $33.3k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy